Skip to content

Walk and Talk: A Randomized Controlled Trial of High Intensive 3MDR Treatment versus Care as Usual for Posttraumatic Stress Disorder.

Walk and Talk: A Randomized Controlled Trial of High Intensive 3MDR Treatment versus Care as Usual for Posttraumatic Stress Disorder. - WATA

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON55588
Enrollment
134
Registered
2018-01-31
Start date
2018-02-15
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posttraumatic Stress Disorder PTSD

Interventions

This study entails two treatment conditions: the experimental 3MDR intervention and conventional TF-PT. The 3MDR intervention is a new type of high intensive exposure treatment, which combines eleme

Sponsors

ARQ Nationaal Psychotrauma Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients with work-related Posttraumatic Stress Disorder - 18 years or older - Meet the DSM-5 criteria for Posttraumatic Stress Disorder - Trauma-focused therapy naive - Master the Dutch language - Must be on a stable dose of medication at commencement of the trial for at least four weeks, and will be asked to keep the dosage stable during the trail.

Exclusion criteria

Exclusion criteria: - Inability to walk - Current severe alcohol or substance use disorder (SUD) - Acute suicidality - Acute psychosis

Design outcomes

Primary

MeasureTime frame
The primary clinical outcome parameter is the difference in PTSD symptom severity measured prior to, during and after treatment. Furthermore, cost-effectiveness will be assessed through health-related quality of life and social costs. Our secondary outcomes include: avoidance behaviour, PTSD severity rated by a spouse, anxiety and depressive symptoms, impairment in daily functioning due to PTSD symptoms, neuropsychological functioning, and for the 3MDR condition physiological responses during sessions.

Secondary

MeasureTime frame
Our secondary outcomes include: avoidance behaviour, PTSD severity rated by a spouse, anxiety and depressive symptoms, impairment in daily functioning due to PTSD symptoms, neuropsychological functioning, and for the 3MDR condition physiological responses during sessions.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Feb 2, 2026